Advancing

ABILITY Neurotech is Europe’s flagship brain-computer interface (BCI) company, spun out of the Wyss Center for Neuro and Bioengineering in Geneva after eight years of research and more than $50M in investment. Our mission is clear: to restore voice, movement and autonomy to people living with severe neurological conditions.

Born from one of the world’s leading nonprofit translational research centers, we carry forward the Wyss Center’s commitment to scientific rigor, patient dignity and real-world clinical impact. Our fully implantable BCI system combines Swiss precision with human-centered design: transmitting raw, lossless brain data at broadband speeds through a discreet optical link to a wearable device, enabling seamless decoding of speech and movement.

This combination of fidelity, safety and usability sets a new benchmark for responsible neurotechnology.

We believe that innovation in the brain must begin with empathy - and that privacy, consent and trust need not be trade-offs for exceptional performance and speed.

As we prepare for first-in-human clinical trials in early 2026, ABILITY stands at the forefront of a movement to redefine what is possible for neurotechnology, and for the patients it serves.